Esperion Therapeutics Stock Probability Of Bankruptcy
| ESPR Stock | USD 2.54 0.03 1.17% |
Esperion | Probability Of Bankruptcy |
Esperion Therapeutics Company probability of distress Analysis
Esperion Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Esperion Therapeutics Probability Of Bankruptcy | Over 70% |
Most of Esperion Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Esperion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Esperion Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Esperion Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Esperion Therapeutics financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share 1.776 | Quarterly Revenue Growth 0.52 | Return On Assets 0.0384 | Return On Equity (2.61) |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Esperion Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Esperion Therapeutics is extremely important. It helps to project a fair market value of Esperion Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Esperion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Esperion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Esperion Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Esperion Therapeutics has a Probability Of Bankruptcy of 70%. This is 61.7% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 75.75% lower than that of the firm.
Esperion Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Esperion Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics of similar companies.Esperion Therapeutics is currently under evaluation in probability of bankruptcy category among its peers.
Esperion Therapeutics Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | (0.51) | (0.47) | (0.84) | (1.16) | (1.02) | (1.07) | |
| Asset Turnover | 0.69 | 0.64 | 0.21 | 0.3 | 0.57 | 0.54 | |
| Gross Profit Margin | (0.18) | 0.99 | 0.82 | 0.64 | 0.63 | 0.52 | |
| Net Debt | (164.6M) | (119.6M) | 51.3M | 136.2M | 458.7M | 481.6M | |
| Total Current Liabilities | 66.1M | 94.1M | 73.4M | 92.3M | 156.2M | 164.0M | |
| Non Current Liabilities Total | 128.4M | 355.3M | 505.2M | 479.4M | 504.6M | 529.8M | |
| Total Assets | 214.4M | 353.3M | 381.6M | 247.9M | 205.8M | 181.9M | |
| Total Current Assets | 211.7M | 345.9M | 329.0M | 246.7M | 201.1M | 160.4M | |
| Total Cash From Operating Activities | (70.3M) | (85.2M) | (263.8M) | (174.8M) | (135.5M) | (128.7M) |
Esperion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Esperion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Esperion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Esperion Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | 0.0384 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 630.63 M | ||||
| Shares Outstanding | 197.04 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 66.33 % | ||||
| Number Of Shares Shorted | 31.25 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 1.69 X | ||||
| Revenue | 116.33 M | ||||
| Gross Profit | (70.42 M) | ||||
| EBITDA | (150.11 M) | ||||
| Net Income | (209.25 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 540.95 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | (135.49 M) | ||||
| Short Ratio | 6.99 X | ||||
| Earnings Per Share | (0.67) X | ||||
| Price To Earnings To Growth | (4.78) X | ||||
| Target Price | 7.51 | ||||
| Number Of Employees | 240 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 500.47 M | ||||
| Total Asset | 205.8 M | ||||
| Retained Earnings | (1.55 B) | ||||
| Working Capital | 44.84 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
| Net Asset | 205.8 M |
About Esperion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
| 0.9 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Esperion Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.77 | PEPG | PepGen | PairCorr |
| 0.72 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.